Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Ryman Healthcare (RYM) / HY24

Dividend suspended as FCF stays $158.4m negative, PBT falls 34%

Headline NPAT declines just 3.8% on a 30.2% tax credit, but underlying profit is flat and pre-lease cash flow sits well below the historical range.

Healthcare / Retirement living

RYM revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY22 revenue trajectory was $508.8m.

RYM operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY22 operating cash flow was $586m.

RYM working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
  • HY23 RYM: Outside range high operating working-capital movement. $281m; 3-period range $-806.6m to $14.8m. Operating working-capital movement: NZ$281.0m, above normal range; 1/3 prior periods had builds averaging NZ$14.8m, and 2 had releases averaging NZ$-479.6m.
  • HY24 RYM: Outside range low operating working-capital movement. $-806.6m; 3-period range $-152.7m to $281m. Operating working-capital movement: NZ$-806.6m, below normal range; 2/3 prior periods had builds averaging NZ$147.9m, and 1 had releases averaging NZ$-152.7m.
Operating working-capital movement: NZ$-806.6m, below normal range; 2/3 prior periods had builds averaging NZ$147.9m, and 1 had releases averaging NZ$-152.7m.

RYM NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
FY22 npat trajectory was $692.9m.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 15 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$2.4b

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.17

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

44.6x

i

Enterprise value compared with recent EBITDA.

P/FCF

12.57x

i

Market cap compared with recent free cash flow.

P/B

0.58x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
29 November 2023
Published
28 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY24 vs HY23

Revenue

$323m

+17.8% ↑ vs $274.2m

EBITDA

$146.3m

— vs —

Net profit after tax

$186.7m

-3.8% ↓ vs $194m

Net cash inflow from operating activities

$337.9m

+38.7% ↑ vs $243.7m

Interim dividend per share

0.0c

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Profit before tax

$143.4m

-34.0% ↓ vs $217.3m

Cash and cash equivalents

$33.3m

+28.7% ↑ vs $25.9m

Total assets

$13.1b

+8.7% ↑ vs $12b

What changed

Pre-lease free cash flow remained materially negative at -$158.4m, $176.9m below the Annolyse historical mean of $18.5m and well outside the supplied range of -$52.5m to +$56.2m

The board responded by zeroing the interim dividend (versus 8.8 cents per share in HY23), the most concrete capital allocation signal in the release.

Top-line momentum was strong: revenue grew 17.8% to $323.0m, above the historical baseline mean of 12.3%. Operating EBITDA rose 7.8% to $146.3m and underlying profit was effectively flat at $139.2m (+0.3%). Statutory PBT fell 34.0% to $143.4m, but NPAT dropped only 3.8% to $186.7m because the effective tax rate swung from -10.7% to +30.2% — a tax credit that masks the operating decline.

Net debt fell to $2.47bn (gearing 33.6%) while capex more than doubled (+130.7%) to $442.8m.

What matters

Headline NPAT overstates resilience

The cleaner read is PBT growth of -34.0% or underlying profit growth of +0.3%, not the -3.8% NPAT decline. The 30.2 percentage point gap between PBT and NPAT growth is entirely tax-driven and will not repeat. Underlying earnings power has flatlined despite strong revenue growth because, per management, lower new sales at sites under development offset operating EBITDA gains.

Free cash flow continues to lag development spend. OCF rose 38.7% to $337.9m, but capex of $442.8m (137.1% of revenue) pushed pre-lease FCF to -$158.4m. The $138.5m improvement versus HY23 is real, but the cash gap to the historical mean explains why the board prioritised balance-sheet repair over a distribution.

Australia segment result collapsed. Australian revenue grew to $52.5m (16.3% of group versus 12.2% prior), but the segment result fell from $65.3m to $12.3m — a $53m swing not explained in the supplied release excerpts. New Zealand result also slipped modestly from $128.7m to $127.0m despite stronger revenue.

Expectations

No stated targets, forward-work disclosures, or second-half shape context were supplied, so this release cannot be judged against management guidance or a backlog conversion path

Management cites "lower new sales in sites under development" as the offset to operating EBITDA growth, which means the second-half read depends on settlement activity at unfinished villages — a variable the release does not quantify. The dividend pause matters because it removes the prior signal of NPAT-based payout discipline (HY23 payout ratio was 22.7%) and ties any future distribution to a cash-flow recovery the release does not yet show.

Quality of result

Operating EBITDA growth of 7.8% and revenue growth of 17.8% are the durable components of the result

Underlying profit being essentially flat indicates operating gains are being absorbed by lower development-stage sales activity rather than translating to bottom-line growth.

The NPAT line is balance-sheet-assisted via a tax credit; the +30.2% effective rate is well outside the supplied historical baseline mean of -23.0%. ROE fell from 5.3% to 3.8% on a much larger equity base ($4.86bn versus $3.63bn), so the increase in retained capital is not yet earning its keep. With capex running at 137.1% of revenue, pre-lease FCF at -$158.4m, and the dividend suspended, the gap between accounting profit and distributable cash is the central durability question. The 231.0% OCF-to-EBITDA conversion looks flattering but reflects resident deposit inflows rather than free cash, and does not survive contact with development capex.

Unresolved

Open questions

When will the interim dividend resume, and what FCF threshold does the board want to see first?
What drove the $53m collapse in the Australian segment result despite revenue growth there?
Why did the effective tax rate swing from -10.7% to +30.2% in a single period?
Can capex moderate from $442.8m as villages complete, and what is the development settlement profile for the second half?
How sensitive is underlying profit to new-sales volumes at development sites, given operating EBITDA grew 7.8% but underlying profit was flat?

This briefing cannot assess management's medium-term development pipeline, scheduled village completions, or sector demand dynamics because the supplied release excerpts do not include that information.

Chat

Ask about RYM HY24

Ask follow-up questions about Ryman Healthcare's HY24 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RYM HY24

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Ryman Healthcare's HY24 result.

When will the interim dividend resume, and what FCF threshold does the board want to see first?Why does "Headline NPAT overstates resilience" matter?How strong was the cash and earnings quality in HY24?What should I watch next for RYM after HY24?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Ryman Healthcare Limited - Announcement Numbers and Financial Statements - 30 September 2023

HY24 / financial report↗

Ryman Healthcare Limited - Media Release and Key Statistics - 30 September 2023

HY24 / media release↗

Ryman Healthcare Limited - Result Presentation - 30 September 2023

HY24 / results presentation↗

Prior comparable period

Ryman Healthcare Limited - Announcement Numbers and financial statements - 30 September 2022

HY23 / financial report↗

Ryman Healthcare Limited - Media Release and Key Statistics - 30 September 2022

HY23 / media release↗

Release context

Ryman Healthcare Limited - Half Year Result Webcast - 30 September 2023

HY24 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 30.2pp, with a distortion flag in the result.

→

Leverage and balance-sheet risk

Net debt / EBITDA is 16.86x for this result.

→

Cash conversion quality

This result converted 231.0% of EBITDA to operating cash flow.

→

Revenue growth context

Revenue growth was 17.8% for this reporting period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when RYM publishes next

Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.